| First Author | Su IJ | Year | 2022 |
| Journal | Int J Mol Sci | Volume | 23 |
| Issue | 1 | PubMed ID | 35008983 |
| Mgi Jnum | J:333643 | Mgi Id | MGI:6853546 |
| Doi | 10.3390/ijms23010556 | Citation | Su IJ, et al. (2022) The Beneficial Effects of Combining Anti-Abeta Antibody NP106 and Curcumin Analog TML-6 on the Treatment of Alzheimer's Disease in APP/PS1 Mice. Int J Mol Sci 23(1) |
| abstractText | Alzheimer's disease (AD) is a progressive neurodegenerative disease with a multifactorial etiology. A multitarget treatment that modulates multifaceted biological functions might be more effective than a single-target approach. Here, the therapeutic efficacy of combination treatment using anti-Abeta antibody NP106 and curcumin analog TML-6 versus monotherapy was investigated in an APP/PS1 mouse model of AD. Our data demonstrate that both combination treatment and monotherapy attenuated brain Abeta and improved the nesting behavioral deficit to varying degrees. Importantly, the combination treatment group had the lowest Abeta levels, and insoluble forms of Abeta were reduced most effectively. The nesting performance of APP/PS1 mice receiving combination treatment was better than that of other APP/PS1 groups. Further findings indicate that enhanced microglial Abeta phagocytosis and lower levels of proinflammatory cytokines were concurrent with the aforementioned effects of NP106 in combination with TML-6. Intriguingly, combination treatment also normalized the gut microbiota of APP/PS1 mice to levels resembling the wild-type control. Taken together, combination treatment outperformed NP106 or TML-6 monotherapy in ameliorating Abeta pathology and the nesting behavioral deficit in APP/PS1 mice. The superior effect might result from a more potent modulation of microglial function, cerebral inflammation, and the gut microbiota. This innovative treatment paradigm confers a new avenue to develop more efficacious AD treatments. |
